Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -153.75% is 88% above its 5-year average of -1319.14%, near the high end of its 5-year range (-25295.45%–566.46%).
98.46% above its 12-month average of -9982.52%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -25295.45%.
EBITDA MARGIN
-153.75%
EBITDA MARGIN AVG TTM
-9982.52%
EBITDA MARGIN AVG 3Y
-2642.92%
EBITDA MARGIN AVG 5Y
-1319.14%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+98.46%
CURRENT VS 3Y AVG
+94.18%
CURRENT VS 5Y AVG
+88.34%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Orchestra BioMed Holdings, Inc.
Market Cap
$349.70M
EBITDA Margin
-153.75%
TTM Avg
-9982.52%
3Y Avg
-2642.92%
5Y Avg
-1319.14%
Market Cap
$352.67M
EBITDA Margin
-1371.56%
TTM Avg
-1336.69%
3Y Avg
-1827.03%
5Y Avg
-11314.18%
Market Cap
$353.88M
EBITDA Margin
-122.86%
TTM Avg
-149.66%
3Y Avg
-152.47%
5Y Avg
-125.05%
Market Cap
$355.36M
EBITDA Margin
18.25%
TTM Avg
18.77%
3Y Avg
18.63%
5Y Avg
20.30%
Market Cap
$344.04M
EBITDA Margin
-870.38%
TTM Avg
-506.32%
3Y Avg
-506.32%
5Y Avg
-506.32%
Market Cap
$355.43M
EBITDA Margin
-25837.05%
TTM Avg
-12960.93%
3Y Avg
-7440.06%
5Y Avg
-7440.06%
Market Cap
$359.53M
EBITDA Margin
-13.98%
TTM Avg
-3.54%
3Y Avg
-384.69%
5Y Avg
-2364.58%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | $349.70M | -153.75% | -9982.52% | -2642.92% | -1319.14% |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | N/A | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $352.67M | -1371.56% | -1336.69% | -1827.03% | -11314.18% |
| Embecta Corp. (EMBC)vs › | $353.00M | 35.21% | 27.25% | 28.55% | 34.67% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | -122.86% | -149.66% | -152.47% | -125.05% |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 18.25% | 18.77% | 18.63% | 20.30% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | -870.38% | -506.32% | -506.32% | -506.32% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | -25837.05% | -12960.93% | -7440.06% | -7440.06% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | -13.98% | -3.54% | -384.69% | -2364.58% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | -271.53% | -418.08% | -211.46% | -940.00% |
Gross Margin
99.3%
EBITDA Margin
-153.8%
Operating Margin
-154.7%
Net Margin
-184.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -25295.45% |
| 2026-03-31 | -19987.27% |
| 2025-12-31 | 22.11% |
| 2025-09-30 | -2349.83% |
| 2025-06-30 | -2302.15% |
| 2025-03-31 | -2170.28% |
| 2024-12-31 | -6558.50% |
| 2024-09-30 | -1648.02% |
| 2024-06-30 | -2157.46% |
| 2024-03-31 | -2314.35% |
| 2023-12-31 | -4736.26% |
| 2023-09-30 | -3449.40% |
| 2023-06-30 | -1407.98% |
| 2023-03-31 | -985.74% |
| 2022-12-31 | -884.68% |
| 2022-09-30 | -860.96% |
| 2022-06-30 | -1891.27% |
| 2022-03-31 | -586.61% |
| 2021-12-31 | 320.38% |
| 2021-09-30 | -325.66% |
| 2021-06-30 | 566.46% |
| 2021-03-31 | -294.68% |
